PMID- 34347947
OWN - NLM
STAT- MEDLINE
DCOM- 20220217
LR  - 20220731
IS  - 2326-5205 (Electronic)
IS  - 2326-5191 (Print)
IS  - 2326-5191 (Linking)
VI  - 74
IP  - 2
DP  - 2022 Feb
TI  - Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European 
      Multicenter Observational Study.
PG  - 295-306
LID - 10.1002/art.41943 [doi]
AB  - OBJECTIVE: Mepolizumab proved to be an efficacious treatment for eosinophilic 
      granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the 
      randomized, controlled MIRRA trial. In a few recently reported studies, 
      successful real-life experiences with the approved dose for treating severe 
      eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study 
      to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 
      300 mg every 4 weeks in a large European EGPA cohort. METHODS: We included all 
      patients with EGPA treated with mepolizumab at the recruiting centers in 
      2015-2020. Treatment response was evaluated from 3 months to 24 months after 
      initiation of mepolizumab. Complete response to treatment was defined as no 
      disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a 
      prednisolone or prednisone dose (or equivalent) of </=4 mg/day. Respiratory 
      outcomes included asthma and ear, nose, and throat (ENT) exacerbations. RESULTS: 
      Two hundred three patients, of whom 191 received a stable dose of mepolizumab 
      (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were 
      included. Twenty-five patients (12.3%) had a complete response to treatment at 3 
      months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 
      months, respectively, and rates were comparable between mepolizumab 100 mg every 
      4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in 
      BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, 
      with no significant differences observed between 100 mg every 4 weeks and 300 mg 
      every 4 weeks. Eighty-two patients (40.4%) experienced asthma exacerbations (57 
      of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 
      mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. 
      Forty-four patients (21.7%) experienced adverse events (AEs), most of which were 
      nonserious AEs (38 of 44). CONCLUSION: Mepolizumab at both 100 mg every 4 weeks 
      and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses 
      should be compared in the setting of a controlled trial.
CI  - (c) 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC 
      on behalf of American College of Rheumatology.
FAU - Bettiol, Alessandra
AU  - Bettiol A
AD  - University of Florence, Florence, Italy.
FAU - Urban, Maria Letizia
AU  - Urban ML
AD  - University of Florence, Florence, Italy.
FAU - Dagna, Lorenzo
AU  - Dagna L
AD  - San Raffaele Hospital, IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Cottin, Vincent
AU  - Cottin V
AD  - Hospices Civils de Lyon and University of Lyon, Lyon, France.
FAU - Franceschini, Franco
AU  - Franceschini F
AD  - ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy.
FAU - Del Giacco, Stefano
AU  - Del Giacco S
AD  - University of Cagliari, Cagliari, Italy.
FAU - Schiavon, Franco
AU  - Schiavon F
AD  - Azienda Ospedaliera-Universitaria di Padova, Padova, Italy.
FAU - Neumann, Thomas
AU  - Neumann T
AD  - Cantonal Hospital St. Gallen, St. Gallen, Switzerland, and Jena University 
      Hospital, Jena, Germany.
FAU - Lopalco, Giuseppe
AU  - Lopalco G
AD  - Polyclinic Hospital, University of Bari, Bari, Italy.
FAU - Novikov, Pavel
AU  - Novikov P
AD  - Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical 
      University, Moscow, Russia.
FAU - Baldini, Chiara
AU  - Baldini C
AD  - University of Pisa, Pisa, Italy.
FAU - Lombardi, Carlo
AU  - Lombardi C
AD  - Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
FAU - Berti, Alvise
AU  - Berti A
AD  - Santa Chiara Hospital and University of Trento, Trento, Italy.
FAU - Alberici, Federico
AU  - Alberici F
AD  - University of Brescia and Spedali Civili Hospital, ASST Spedali Civili di 
      Brescia, Brescia, Italy.
FAU - Folci, Marco
AU  - Folci M
AD  - Humanitas Clinical and Research Center, IRCCS and Humanitas University, IRCCS, 
      Milan, Italy.
FAU - Negrini, Simone
AU  - Negrini S
AD  - IRCCS Ospedale Policlinico San Martino and University of Genoa, Genoa, Italy.
FAU - Sinico, Renato Alberto
AU  - Sinico RA
AD  - University of Milano Bicocca, Monza, Italy.
FAU - Quartuccio, Luca
AU  - Quartuccio L
AD  - University of Udine, Azienda sanitaria universitaria Friuli Centrale Udine, 
      Udine, Italy.
FAU - Lunardi, Claudio
AU  - Lunardi C
AD  - University of Verona, Italy.
FAU - Parronchi, Paola
AU  - Parronchi P
AD  - University of Florence, Florence, Italy.
FAU - Moosig, Frank
AU  - Moosig F
AD  - Rheumazentrum Schleswig-Holstein Mitte, Neumunster, Germany.
FAU - Espigol-Frigole, Georgina
AU  - Espigol-Frigole G
AD  - Hospital Clinic, University of Barcelona and Institut d'investigacions 
      Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
FAU - Schroeder, Jan
AU  - Schroeder J
AD  - ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
FAU - Kernder, Anna Luise
AU  - Kernder AL
AD  - Heinrich Heine University Dusseldorf, Dusseldorf, Germany.
FAU - Monti, Sara
AU  - Monti S
AD  - Policlinico S. Matteo Fondazione, IRCCS, University of Pavia, Pavia, Italy.
FAU - Silvagni, Ettore
AU  - Silvagni E
AD  - University of Ferrara, Ferrara, Italy.
FAU - Crimi, Claudia
AU  - Crimi C
AD  - Policlinico-Vittorio Emanuele San Marco University Hospital, Catania, Italy.
FAU - Cinetto, Francesco
AU  - Cinetto F
AD  - University of Padova, Padova, Italy.
FAU - Fraticelli, Paolo
AU  - Fraticelli P
AD  - University Hospital Ospedali Riuniti, Ancona, Italy.
FAU - Roccatello, Dario
AU  - Roccatello D
AD  - San Giovanni Bosco Hospital and University of Turin, Turin, Italy.
FAU - Vacca, Angelo
AU  - Vacca A
AD  - Aldo Moro University of Bari, Bari, Italy.
FAU - Mohammad, Aladdin J
AU  - Mohammad AJ
AD  - Lund University, Skane University Hospital, Lund, Sweden, and University of 
      Cambridge, Cambridge, UK.
FAU - Hellmich, Bernhard
AU  - Hellmich B
AD  - Medius Kliniken, University of Tubingen, Kirchheim unter Teck, Germany.
FAU - Samson, Maxime
AU  - Samson M
AD  - Dijon University Hospital, Dijon, France.
FAU - Bargagli, Elena
AU  - Bargagli E
AD  - University of Siena, Siena, Italy.
FAU - Cohen Tervaert, Jan Willem
AU  - Cohen Tervaert JW
AD  - University of Alberta, Edmonton, Alberta, Canada, and Maastricht University, 
      Maastricht, The Netherlands.
FAU - Ribi, Camillo
AU  - Ribi C
AD  - University Hospital Center of Lausanne, Lausanne, Switzerland.
FAU - Fiori, Davide
AU  - Fiori D
AD  - University of Florence, Florence, Italy.
FAU - Bello, Federica
AU  - Bello F
AD  - University of Florence, Florence, Italy.
FAU - Fagni, Filippo
AU  - Fagni F
AD  - University of Florence, Florence, Italy.
FAU - Moroni, Luca
AU  - Moroni L
AD  - San Raffaele Hospital, IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Ramirez, Giuseppe Alvise
AU  - Ramirez GA
AD  - San Raffaele Hospital, IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Nasser, Mouhamad
AU  - Nasser M
AD  - Hospices Civils de Lyon and University of Lyon, Lyon, France.
FAU - Marvisi, Chiara
AU  - Marvisi C
AD  - Azienda USL-IRCCS di Reggio Emilia, IRCCS, and Universita di Modena e Reggio 
      Emilia, Reggio Emilia, Italy.
FAU - Toniati, Paola
AU  - Toniati P
AD  - ASST Spedali Civili of Brescia, Brescia, Italy.
FAU - Firinu, Davide
AU  - Firinu D
AD  - University of Cagliari, Cagliari, Italy.
FAU - Padoan, Roberto
AU  - Padoan R
AD  - Azienda Ospedaliera-Universitaria di Padova, Padova, Italy.
FAU - Egan, Allyson
AU  - Egan A
AD  - University of Cambridge, Cambridge, UK.
FAU - Seeliger, Benjamin
AU  - Seeliger B
AD  - Hannover Medical School, Hannover, Germany.
FAU - Iannone, Florenzo
AU  - Iannone F
AD  - Polyclinic Hospital, University of Bari, Bari, Italy.
FAU - Salvarani, Carlo
AU  - Salvarani C
AD  - Azienda USL-IRCCS di Reggio Emilia, IRCCS, and Universita di Modena e Reggio 
      Emilia, Reggio Emilia, Italy.
FAU - Jayne, David
AU  - Jayne D
AD  - University of Cambridge, Cambridge, UK.
FAU - Prisco, Domenico
AU  - Prisco D
AD  - University of Florence, Florence, Italy.
FAU - Vaglio, Augusto
AU  - Vaglio A
AD  - University of Florence and Meyer Children's Hospital, Florence, Italy.
FAU - Emmi, Giacomo
AU  - Emmi G
AD  - University of Florence, Florence, Italy.
CN  - European EGPA Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20211230
PL  - United States
TA  - Arthritis Rheumatol
JT  - Arthritis & rheumatology (Hoboken, N.J.)
JID - 101623795
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 90Z2UF0E52 (mepolizumab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Drug Administration Schedule
MH  - Eosinophilia/complications/*drug therapy
MH  - Female
MH  - Granulomatosis with Polyangiitis/complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC9305132
FIR - Ahmad, Kais
IR  - Ahmad K
FIR - Beccalli, Mirko
IR  - Beccalli M
FIR - Bonnotte, Bernard
IR  - Bonnotte B
FIR - Bortolotti, Roberto
IR  - Bortolotti R
FIR - Cariddi, Adriana
IR  - Cariddi A
FIR - Caminati, Marco
IR  - Caminati M
FIR - Cid, Maria C
IR  - Cid MC
FIR - Deidda, Margherita
IR  - Deidda M
FIR - Delvino, Paolo
IR  - Delvino P
FIR - Scala, Gerardo Di
IR  - Scala GD
FIR - Felicetti, Mara
IR  - Felicetti M
FIR - Ferro, Francesco
IR  - Ferro F
FIR - Furini, Federica
IR  - Furini F
FIR - Gelain, Elena
IR  - Gelain E
FIR - Ghirelli, Giulia
IR  - Ghirelli G
FIR - Holle, Julia
IR  - Holle J
FIR - Losappio, Laura Michelina
IR  - Losappio LM
FIR - Mahr, Alfred
IR  - Mahr A
FIR - Malandrino, Danilo
IR  - Malandrino D
FIR - Marhhold, Juliane
IR  - Marhhold J
FIR - Mattioli, Irene
IR  - Mattioli I
FIR - Moi, Laura
IR  - Moi L
FIR - Moiseev, Sergey
IR  - Moiseev S
FIR - Muratore, Francesco
IR  - Muratore F
FIR - Nolasco, Santi
IR  - Nolasco S
FIR - Olivieri, Bianca
IR  - Olivieri B
FIR - Palermo, Adalgisa
IR  - Palermo A
FIR - Regola, Francesca
IR  - Regola F
FIR - Sander, Oliver
IR  - Sander O
FIR - Scarpa, Riccardo
IR  - Scarpa R
FIR - Sciascia, Savino
IR  - Sciascia S
FIR - Silvestri, Elena
IR  - Silvestri E
FIR - Susca, Nicola
IR  - Susca N
FIR - Terrier, Benjamin
IR  - Terrier B
FIR - Treppo, Elena
IR  - Treppo E
FIR - Trezzi, Barbara
IR  - Trezzi B
FIR - Uzzo, Martina
IR  - Uzzo M
FIR - Vitiello, Gianfranco
IR  - Vitiello G
FIR - Yacyshyn, Elaine
IR  - Yacyshyn E
EDAT- 2021/08/05 06:00
MHDA- 2022/02/19 06:00
PMCR- 2022/07/22
CRDT- 2021/08/04 17:29
PHST- 2021/06/18 00:00 [revised]
PHST- 2021/05/04 00:00 [received]
PHST- 2021/07/29 00:00 [accepted]
PHST- 2021/08/05 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/08/04 17:29 [entrez]
PHST- 2022/07/22 00:00 [pmc-release]
AID - ART41943 [pii]
AID - 10.1002/art.41943 [doi]
PST - ppublish
SO  - Arthritis Rheumatol. 2022 Feb;74(2):295-306. doi: 10.1002/art.41943. Epub 2021 
      Dec 30.